Marburg Virus Disease Therapeutics Market Snapshot (2023 to 2033)

The global Marburg virus disease therapeutics market is expected to garner a market value of US$ 90.74 Million in 2023 and is expected to accumulate a market value of US$ 155 Million by registering a CAGR of 5.5% in the forecast period 2023 to 2033. The growth of the Marburg virus disease therapeutics market can be attributed to the increasing prevalence of the Marburg virus in different geographical regions. The demand for Marburg virus disease therapeutics registered a CAGR of 4.1% in the historical period 2018 to 2022

The Marburg virus disease market is expected to witness growth owing to the increasing prevalence of the ailment. In addition, the COVID-19 virus is fueling research and development activities for innovating therapeutics treatment for the Marburg virus diseases therapeutics market.

Data Points Key Statistics
Expected Market Value (2023) US$ 90.74 Million
Anticipated Forecast Value (2033) US$ 155 Million
Projected Growth Rate (2023 to 2033) 5.5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Marburg Virus Disease Therapeutics Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Marburg virus disease therapeutics reflected a value CAGR of 4.1% during the historic period, 2018 to 2022.

The similar symptoms of COVID-19 and Marburg virus diseases have created tremendous pressure on the healthcare industries, especially in the Middle East and South Africa. Thus, the demand for innovative treatments to reduce the intensity of the viruses is expected to boost the overall market in the upcoming years.

Furthermore, extensive research and development for innovating therapeutics are favoring the market's growth. Thus, the Marburg virus disease therapeutics market is expected to register a CAGR of 5.5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Marburg Virus Disease Therapeutics Market?

Exposure to the Marburg virus increases cases of contracting the virus among people

The rise in the healthcare sector globally is escalating the growth of the Marburg virus disease market. Marburg virus refers to the type of virus that belongs to the genus Marburgvirus in the family Filoviridae. This virus causes a severe viral disease that is known as Marburg virus disease (MHF), in both humans and nonhuman primates. MHF is generally characterized by systemic viral replication, abnormal inflammatory responses, and immunosuppression, similar to the Ebola virus.

Marburg can spread through human-to-human transmission via direct contact (through broken skin or mucous membranes) with the blood, secretions, organs, or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, and clothing) contaminated with these fluids. Thus, these factors are increasing the cases of the Marburg virus disease across the globe.

Increase in the prevalence of unhealthy lifestyles along with research and development efforts contributing to market growth

The surge in the number of people suffering from Marburg virus disease across the globe is one of the major factors driving the growth of the Marburg virus disease market. The rise in awareness among people regarding rare disorders and increased demand for various drugs for treating symptoms such as nausea, vomiting, chest pain, diarrhea, and jaundice, among others accelerate the market growth.

The rise in the number of clinical trials for the enhancement of drugs and therapies and the increase in the prevalence of unhealthy lifestyles of people further influence the market. Additionally, growth in awareness, the surge in investments, development in technology, change in lifestyle and rise in healthcare expenditure positively affect the Marburg virus disease market. Furthermore, advancements in medications extend profitable opportunities to the market players in the forecast period of 2023 to 2033.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Marburg Virus Disease Therapeutics Market?

Lack of awareness amongst people and the expensive nature of treatment derailing market growth

On the other hand, the high cost associated with the treatment and diagnosis is expected to obstruct market growth. Moreover, the expenditure required for investing in research and development for innovating therapeutics for treating the Marburg virus is more. This, in turn, is hampering the growth of the market.

Low awareness among people is projected to challenge the Marburg virus disease market in 2023 to 2023. Thus. Late detection of the ailment reduces the chances of receiving proper treatment to cure the ailment. All these factors are creating obstacles to the growth of the Marburg virus diseases therapeutics market.

Region-Wise Insights            

Improved Healthcare Infrastructure Boosting Therapeutics Treatment for Marburg Viral Diseases Therapeutics Treatment in North America?

Investment in research and development by key players favoring the market growth

North America dominates the Marburg virus disease market due to the advanced medical care system and infrastructure within the region. Moreover, the increasing prevalence of Marburg viral diseases in the region is bolstering the need for therapeutics.

Furthermore, the strong presence of key players in the region is favoring the growth of the market. Investment in research and development to innovate novel therapeutic treatment is another factor driving the growth of the market. the presence of research institutes in the USA. and Canada is bolstering the growth of the Marburg virus diseases therapeutics market in North America. Thus, North America is expected to possess a 43% market share of the Marburg virus diseases therapeutics market in North America in 2023.

Increasing Prevalence of Marburg Virus Diseases in the Middle East and South Africa Creating Lucrative Opportunities for Therapeutics Treatment?

Absence of Vaccines increasing dependability on Therapeutics Treatment

Owing to the increasing predominance of Ebola Virus Disease (EVD) or Ebola Virus disease and Marburg Virus Disease (MVD) or Marburg Virus disease, caused by filoviruses termed Ebola virus and Marburg virus in African countries like Guinea, the Democratic Republic of the Congo, Uganda, Angola, Kenya, and South Africa, as per updates by World Health Organization (WHO), in the Rest of the world region.

Ebola & Marburg Infections market growth is being driven by the increasing Ebola outbreaks in Guinea which then spread to Sierra Leone and Liberia and cases of Marburg Virus Disease (MVD) in Uganda and Angola. The Democratic Republic of the Congo, Kenya, and South Africa. However, as per World Health Organization (WHO), presently, there are no vaccines or antiviral treatments certified for Marburg Virus Disease (MVD) or Marburg Virus disease, which is one of the major factors hampering the growth of the Ebola & Marburg Infections Market. Thus, the Middle East and Africa are expected to possess a 39% market share for Marburg viral disease therapeutic treatment market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Availability of Various Treatments Making Hospitals Convenient for Treatment for Marburg Virus Disease Therapeutics Market?

Favorable reimbursement policies make hospitals a viable option for treatment

On the basis of end users, the Marburg virus diseases market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centres, and Others. The hospital segment is expected to hold the largest market share for Marburg virus disease therapeutics. This is owing to the availability of various treatments and diagnostics in hospitals. In addition, the presence of healthcare experts and cardiologists plays a key role in the wide usage of hospitals for the treatment of Marburg virus disease therapeutics.

In addition, initiatives by government authorities to support the treatment of Marburg virus disease therapeutics, especially in hospitals, favor the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of Marburg virus disease therapeutics. Thus, the hospital segment is expected to hold a 45% market share of the Marburg virus disease therapeutics market in 2023.

Market Competition

Key players in the Marburg virus disease therapeutics market are Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, BioCryst Pharmaceuticals, Bavarian Nordic, Bio-Rad Laboratories, Inc, AlphaVax, GW Pharmaceuticals plc, Takeda Pharmaceutical Company Limited, Alexion Pharmaceuticals, Inc, Mapp Biopharmaceutical, Collaborations Pharmaceuticals, Inc, Emergent BioSolutions Inc, BioMarin and Sarepta Therapeutics, Alkido Pharma, Biofactura

  • BioCryst Pharmaceuticals, a key player in the Marburg virus disease therapeutics market is focusing on undertaking research and development for understanding the nature of the virus and innovating therapeutic treatments for the same.
  • Bio-Rad Laboratories, Inc, another key player in the Marburg virus disease therapeutics market is integrating technology to understand the ailment and offering medication for treating the virus.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 90.74 Million
Market Value in 2033 US$ 155 Million
Growth Rate CAGR of 5.5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2017 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Drug Classification
  • Route of Administration
  • End Users
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • The USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Amicus Therapeutics Inc.
  • Alexion Pharmaceuticals Inc.
  • BioCryst Pharmaceuticals
  • Bavarian Nordic
  • Bio-Rad Laboratories, Inc.
  • AlphaVax
  • GW Pharmaceuticals Plc
  • Takeda Pharmaceutical Company Limited
  • Mapp Biopharmaceutical
  • Collaborations Pharmaceuticals Inc.
  • Emergent BioSolutions Inc.
  • BioMarin and Sarepta Therapeutics
  • Alkido Pharma
  • Biofactura

Key Segments Profiled in the Marburg Virus Disease Therapeutics Industry Survey

By Drug Classification:

  • Antiemetic
  • Nitro-glycerine
  • Loperamide
  • Antibiotics
  • Others

By Route of Administration:

  • Injectable
  • Oral
  • Parenteral

By End Users:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centres
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Current Market Valuation?

The marburg virus disease therapeutics market is valued at US$ 90.74 million In 2023.

What is the Expected Market Growth Rate until 2033?

The market is likely to experience a 5.5% CAGR until 2033.

Which End-user segment is Likely to Dominate the market until 2033?

The hospital segment is expected to dominate the market based on end user.

How is the Historical Performance of the Market?

The market registered a CAGR of 4.1% from 2018 to 2022.

Which Region is Estimated to Dominate the Market through 2033?

North America is estimated to dominate the market through 2033.

Table of Content

1. Executive Summary | Marburg Virus Disease Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Classification

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ million) Analysis By Drug Classification, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Classification, 2023 to 2033

        5.3.1. Antiemetic

        5.3.2. Nitro-glycerine

        5.3.3. Loperamide

        5.3.4. Antibiotics

        5.3.5. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Classification, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Classification, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Injectable

        6.3.2. Oral

        6.3.3. Parenteral

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ million) Analysis By End-Users, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End-Users, 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Specialty Clinics

        7.3.3. Ambulatory Surgical Centres

        7.3.4. Others

    7.4. Y-o-Y Growth Trend Analysis By End-Users, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End-Users, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Hospital Pharmacy

        8.3.2. Retail Pharmacy

        8.3.3. Online Pharmacy

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. The USA

            10.2.1.2. Canada

        10.2.2. By Drug Classification

        10.2.3. By Route of Administration

        10.2.4. By End-Users

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Classification

        10.3.3. By Route of Administration

        10.3.4. By End-Users

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Classification

        11.2.3. By Route of Administration

        11.2.4. By End-Users

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Classification

        11.3.3. By Route of Administration

        11.3.4. By End-Users

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. The United Kingdom

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Drug Classification

        12.2.3. By Route of Administration

        12.2.4. By End-Users

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Classification

        12.3.3. By Route of Administration

        12.3.4. By End-Users

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Rest of South Asia

        13.2.2. By Drug Classification

        13.2.3. By Route of Administration

        13.2.4. By End-Users

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Classification

        13.3.3. By Route of Administration

        13.3.4. By End-Users

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Classification

        14.2.3. By Route of Administration

        14.2.4. By End-Users

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Classification

        14.3.3. By Route of Administration

        14.3.4. By End-Users

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. Australia

            15.2.1.2. New Zealand

        15.2.2. By Drug Classification

        15.2.3. By Route of Administration

        15.2.4. By End-Users

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Classification

        15.3.3. By Route of Administration

        15.3.4. By End-Users

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Drug Classification

        16.2.3. By Route of Administration

        16.2.4. By End-Users

        16.2.5. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Drug Classification

        16.3.3. By Route of Administration

        16.3.4. By End-Users

        16.3.5. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. The USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Drug Classification

            17.1.2.2. By Route of Administration

            17.1.2.3. By End-Users

            17.1.2.4. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Drug Classification

            17.2.2.2. By Route of Administration

            17.2.2.3. By End-Users

            17.2.2.4. By Distribution Channel

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Drug Classification

            17.3.2.2. By Route of Administration

            17.3.2.3. By End-Users

            17.3.2.4. By Distribution Channel

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Drug Classification

            17.4.2.2. By Route of Administration

            17.4.2.3. By End-Users

            17.4.2.4. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Drug Classification

            17.5.2.2. By Route of Administration

            17.5.2.3. By End-Users

            17.5.2.4. By Distribution Channel

    17.6. The United Kingdom

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Drug Classification

            17.6.2.2. By Route of Administration

            17.6.2.3. By End-Users

            17.6.2.4. By Distribution Channel

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Drug Classification

            17.7.2.2. By Route of Administration

            17.7.2.3. By End-Users

            17.7.2.4. By Distribution Channel

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Drug Classification

            17.8.2.2. By Route of Administration

            17.8.2.3. By End-Users

            17.8.2.4. By Distribution Channel

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Drug Classification

            17.9.2.2. By Route of Administration

            17.9.2.3. By End-Users

            17.9.2.4. By Distribution Channel

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Drug Classification

            17.10.2.2. By Route of Administration

            17.10.2.3. By End-Users

            17.10.2.4. By Distribution Channel

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Drug Classification

            17.11.2.2. By Route of Administration

            17.11.2.3. By End-Users

            17.11.2.4. By Distribution Channel

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Drug Classification

            17.12.2.2. By Route of Administration

            17.12.2.3. By End-Users

            17.12.2.4. By Distribution Channel

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Drug Classification

            17.13.2.2. By Route of Administration

            17.13.2.3. By End-Users

            17.13.2.4. By Distribution Channel

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Drug Classification

            17.14.2.2. By Route of Administration

            17.14.2.3. By End-Users

            17.14.2.4. By Distribution Channel

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Drug Classification

            17.15.2.2. By Route of Administration

            17.15.2.3. By End-Users

            17.15.2.4. By Distribution Channel

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Drug Classification

            17.16.2.2. By Route of Administration

            17.16.2.3. By End-Users

            17.16.2.4. By Distribution Channel

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Drug Classification

            17.17.2.2. By Route of Administration

            17.17.2.3. By End-Users

            17.17.2.4. By Distribution Channel

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Drug Classification

            17.18.2.2. By Route of Administration

            17.18.2.3. By End-Users

            17.18.2.4. By Distribution Channel

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Drug Classification

            17.19.2.2. By Route of Administration

            17.19.2.3. By End-Users

            17.19.2.4. By Distribution Channel

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Drug Classification

            17.20.2.2. By Route of Administration

            17.20.2.3. By End-Users

            17.20.2.4. By Distribution Channel

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Drug Classification

            17.21.2.2. By Route of Administration

            17.21.2.3. By End-Users

            17.21.2.4. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Drug Classification

        18.3.3. By Route of Administration

        18.3.4. By End-Users

        18.3.5. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Amicus Therapeutics, Inc.

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Alexion Pharmaceuticals, Inc.

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. BioCryst Pharmaceuticals

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. Bavarian Nordic

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Bio-Rad Laboratories, Inc.

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. AlphaVax

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. GW Pharmaceuticals plc.

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Takeda Pharmaceutical Company Limited

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Alexion Pharmaceuticals, Inc.

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Mapp Biopharmaceutical

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

        19.1.11. Collaborations Pharmaceuticals, Inc.

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

        19.1.12. Emergent BioSolutions Inc.

            19.1.12.1. Overview

            19.1.12.2. Product Portfolio

            19.1.12.3. Profitability by Market Segments

            19.1.12.4. Sales Footprint

            19.1.12.5. Strategy Overview

                19.1.12.5.1. Marketing Strategy

        19.1.13. BioMarin and Sarepta Therapeutics

            19.1.13.1. Overview

            19.1.13.2. Product Portfolio

            19.1.13.3. Profitability by Market Segments

            19.1.13.4. Sales Footprint

            19.1.13.5. Strategy Overview

                19.1.13.5.1. Marketing Strategy

        19.1.14. Alkido Pharma

            19.1.14.1. Overview

            19.1.14.2. Product Portfolio

            19.1.14.3. Profitability by Market Segments

            19.1.14.4. Sales Footprint

            19.1.14.5. Strategy Overview

                19.1.14.5.1. Marketing Strategy

        19.1.15. Biofactura

            19.1.15.1. Overview

            19.1.15.2. Product Portfolio

            19.1.15.3. Profitability by Market Segments

            19.1.15.4. Sales Footprint

            19.1.15.5. Strategy Overview

                19.1.15.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Antiviral Immunoglobulin Market

July 2017

REP-GB-4398

June 2023

240 pages

Healthcare

Human Immunodeficiency Virus Type 1 (HIV 1) Market

December 2022

REP-GB-16202

280 pages

Healthcare

Arthropod-borne Viral Infections Testing Market

February 2022

REP-GB-11572

July 2022

206 pages

Healthcare

Covid-19 Diagnostics Market

August 2020

REP-GB-12366

280 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Marburg Virus Disease Therapeutics Market